A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
Crossref DOI link: https://doi.org/10.1007/s10549-014-3239-5
Published Online: 2014-12-21
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Elster, N.
Cremona, M.
Morgan, C.
Toomey, S.
Carr, A.
O’Grady, A.
Hennessy, B. T.
Eustace, A. J.
Text and Data Mining valid from 2014-12-21